News

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time with each patient to provide the best care.

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.

The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.

Patient-reported outcomes were consistent between patients with RCC using tivozanib/nivolumab and tivozanib monotherapy according to study findings.

Erica S. Doubleday, MS, FNP-C, BSN, RN, discussed taking advantage of available resources to provide comprehensive care for patients with breast cancer.

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.

Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared with chemotherapy, monoclonal antibodies, and protease inhibitors.

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, RN.

Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure.

Enfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy.

Real-world data demonstrate significant outcome improvements with enfortumab vedotin in patients with unresectable or metastatic urothelial carcinoma.

Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, discontinuation rates were low across all groups.

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.